BOSTON, MA. – Kim Lewis, PhD, Unviersity Distinguished Professor and Director of Antimicrobial Discovery Center, Northeastern.

Dr. Kim Lewis is a University Distinguished Professor and Director, Antimicrobial Discovery Center at Northeastern University in Boston, and a Fellow of the American Society of Microbiology.

He obtained his Ph.D. in Biochemistry from Moscow University in 1980, and has been on the Faculty of MIT, University of Maryland, and Tufts University prior to coming to Northeastern.

Dr. Lewis has authored over 100 papers and is an inventor on several patents. His more notable findings include the development of general methods to grow previously uncultured bacteria that make up >99% of biodiversity on the planet, the discovery of the culprit of recalcitrant biofilm infections, drug-tolerant persister cells; antimicrobials for sterilizing biofilm infections and killing M. tuberculosis, and the discovery of teixobactin which is largely free of resistance development.

Dr. Lewis presented over 100 invited talks. Dr. Lewis has been a permanent member of the Drug Discovery and Drug Resistance NIH Study Section, and Chair of two NIH Study Sections on Drug Discovery. Dr. Lewis has served as a panelist and contributor to the National Academies Institute of Medicine reports on antibiotic resistance in 2010, 2011 and 2014, and the European Academies Science Advisory Meeting in 2014. Dr. Lewis is a member of Faculty 1000, a world-wide panel of experts evaluating research advancements. He is a recipient of the MIT C.E. Reed Faculty Initiative Award for an innovative research project (1992), is a recipient of the NIH Director’s Transformative Grant (2009), and a recipient of the Lyme Research Alliance award in 2014.

Apart from his work in Academia, Dr. Lewis has served as a consultant to the Pharmaceutical Industry, The Biotech, and is a founder of two Biotech Companies, NovoBiotic Pharmaceuticals, and Arietis Corporation.

Our Sponsors